WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H561510
CAS#: 150045-18-4
Description: MS-444 is a small-molecule inhibitor of HuR. HuR is an RNA-binding protein implicated in immune homeostasis and various cancers, including colorectal cancer.
Hodoodo Cat#: H561510
Name: MS-444
CAS#: 150045-18-4
Chemical Formula: C13H10O4
Exact Mass: 230.06
Molecular Weight: 230.210
Elemental Analysis: C, 67.82; H, 4.38; O, 27.80
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: MS-444; MS 444; MS444;
IUPAC/Chemical Name: 5,8-Dihydroxy-3-methyl-naphtho[2,3-c]furan-4(9H)-one
InChi Key: TZUYDLKHNQUNKS-UHFFFAOYSA-N
InChi Code: InChI=1S/C13H10O4/c1-6-11-7(5-17-6)4-8-9(14)2-3-10(15)12(8)13(11)16/h2-3,5,14-15H,4H2,1H3
SMILES Code: O=C(C1=C(C)OC=C1C2)C3=C2C(O)=CC=C3O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 230.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Lang M, Berry D, Passecker K, Mesteri I, Bhuju S, Ebner F, Sedlyarov V, Evstatiev R, Dammann K, Loy A, Kuzyk O, Kovarik P, Khare V, Beibel M, Roma G, Meisner-Kober N, Gasche C. HuR Small-Molecule Inhibitor Elicits Differential Effects in Adenomatosis Polyposis and Colorectal Carcinogenesis. Cancer Res. 2017 May 1;77(9):2424-2438. doi: 10.1158/0008-5472.CAN-15-1726. Epub 2017 Feb 20. PubMed PMID: 28428272.
2: Bhople S, Gaikwad S, Deshmukh S, Bonde S, Gade A, Sen S, Brezinska A, Dahm H, Rai M. Myxobacteria-mediated synthesis of silver nanoparticles and their impregnation in wrapping paper used for enhancing shelf life of apples. IET Nanobiotechnol. 2016 Dec;10(6):389-394. doi: 10.1049/iet-nbt.2015.0111. PubMed PMID: 27906139.
3: Blanco FF, Preet R, Aguado A, Vishwakarma V, Stevens LE, Vyas A, Padhye S, Xu L, Weir SJ, Anant S, Meisner-Kober N, Brody JR, Dixon DA. Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis. Oncotarget. 2016 Nov 8;7(45):74043-74058. doi: 10.18632/oncotarget.12189. PubMed PMID: 27677075; PubMed Central PMCID: PMC5342034.
4: Romeo C, Weber MC, Zarei M, DeCicco D, Chand SN, Lobo AD, Winter JM, Sawicki JA, Sachs JN, Meisner-Kober N, Yeo CJ, Vadigepalli R, Tykocinski ML, Brody JR. HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells. Mol Cancer Res. 2016 Jul;14(7):599-611. doi: 10.1158/1541-7786.MCR-15-0448. Epub 2016 Apr 6. PubMed PMID: 27053682; PubMed Central PMCID: PMC5312260.
5: Moradi F, Berglund P, Linnskog R, Leandersson K, Andersson T, Prasad CP. Dual mechanisms of action of the RNA-binding protein human antigen R explains its regulatory effect on melanoma cell migration. Transl Res. 2016 Jun;172:45-60. doi: 10.1016/j.trsl.2016.02.007. Epub 2016 Feb 23. PubMed PMID: 26970271.
6: Blanco FF, Jimbo M, Wulfkuhle J, Gallagher I, Deng J, Enyenihi L, Meisner-Kober N, Londin E, Rigoutsos I, Sawicki JA, Risbud MV, Witkiewicz AK, McCue PA, Jiang W, Rui H, Yeo CJ, Petricoin E, Winter JM, Brody JR. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells. Oncogene. 2016 May;35(19):2529-41. doi: 10.1038/onc.2015.325. Epub 2015 Sep 21. PubMed PMID: 26387536.
7: Takeuchi O. HuR keeps interferon-β mRNA stable. Eur J Immunol. 2015 May;45(5):1296-9. doi: 10.1002/eji.201545616. PubMed PMID: 25824620.
8: Meisner NC, Hintersteiner M, Mueller K, Bauer R, Seifert JM, Naegeli HU, Ottl J, Oberer L, Guenat C, Moss S, Harrer N, Woisetschlaeger M, Buehler C, Uhl V, Auer M. Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR. Nat Chem Biol. 2007 Aug;3(8):508-15. Epub 2007 Jul 15. PubMed PMID: 17632515.
9: Tatsuta K, Yoshimoto T, Gunji H. Total synthesis of MS-444, a myosin light chain kinase inhibitor. J Antibiot (Tokyo). 1997 Mar;50(3):289-90. PubMed PMID: 9439708.
10: Tatsuta K, Yoshimoto T, Gunji H. Total synthesis of MS-444, a myosin light chain kinase inhibitor. J Antibiot (Tokyo). 1997 Mar;50(3):289-90. PubMed PMID: 9127208.
11: Aotani Y, Saitoh Y. Structure determination of MS-444; a new myosin light chain kinase inhibitor. J Antibiot (Tokyo). 1995 Sep;48(9):952-3. PubMed PMID: 7592061.
12: Nakanishi S, Chiba S, Yano H, Kawamoto I, Matsuda Y. MS-444, a new inhibitor of myosin light chain kinase from Micromonospora sp. KY7123. J Antibiot (Tokyo). 1995 Sep;48(9):948-51. PubMed PMID: 7592060.